Equity Profile

BEAM

Beam Therapeutics Inc.

Health CareBiotechnology$3.4B

Mar14Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing technology....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and validate its business model.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BEAM Q2-2026 Earnings Preview

Context

Company Snapshot

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing technology. As part of the health care sector, Beam aims to address genetic diseases, which is a major theme in the ongoing evolution of medical treatments.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+35.03%

Avg Stock Reaction

-2.71%

Last Quarter Recap

In the last quarter, Beam reported an EPS of -$0.91, slightly missing analyst expectations. The stock reacted negatively, dropping 2.69% the following day.

Management Promises & Guidance

Focus on advancing clinical trials for its lead programs.
Commitment to enhancing its base editing technology.
Plans to provide more transparency on future revenue projections.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Beam has shown volatility in its earnings history. Investors are keenly watching for any signs of progress in clinical trials.

Bull Case

If Beam demonstrates significant advancements in its clinical trials, it could lead to increased investor confidence and a potential stock price rally.

Bear Case

Conversely, if the company fails to provide clear progress or misses expectations again, it could lead to further declines in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What progress has been made in clinical trials for Beam's lead programs?

The success or failure of these trials can heavily influence investor sentiment and the stock's future performance.

Will management provide updated revenue projections for the upcoming quarters?

Clear guidance on revenue can help investors gauge the company's growth trajectory and financial health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Beam's potential for clinical trial success, given its innovative base editing technology, which could lead to breakthroughs in treating genetic diseases.

Supporting Evidence

Beam's recent advancements in technology may not be fully reflected in current market expectations.

The options market is pricing in a larger move than historical averages suggest, indicating potential for a surprise.

Past performance shows that the company has a 50% beat rate, suggesting that positive surprises are possible.

Key Risk

If clinical trial results exceed expectations, it could significantly shift market sentiment in Beam's favor.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Beam's ability to translate its innovative technology into tangible financial results.

Bull Confirmed If

Demonstrating a clear path to commercialization for its lead programs would support a bullish outlook.

Bear Confirmed If

Failure to provide any positive updates on clinical trials or revenue guidance would confirm a bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±10.21%

Historical Avg

±6.2%

Pricing rich

The options market is pricing in a significant move, suggesting that traders anticipate volatility around the earnings report.

Options are pricing ±10.2% while BEAM has averaged ±6.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

74.1%

Calls (99K)P/C Ratio: 0.03Puts (3K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Beam beats expectations and raises guidance, history suggests a potential stock increase of around 2.09%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may react neutrally, reflecting the uncertainty.

Miss

A miss could lead to a decline of about 7.50%, indicating continued investor skepticism about the company's growth prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for lead programs.
2Any changes to revenue projections or guidance.
3Management's commentary on competitive positioning in the biotechnology space.
4Insights into partnerships or collaborations that could enhance growth.
5Future plans for product development and commercialization timelines.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

GitLab Inc.

Company Snapshot

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing technology....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and validate its business model.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BEAM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+35.03%

Avg Stock Reaction

-2.71%

Last Quarter Recap

In the last quarter, Beam reported an EPS of -$0.91, slightly missing analyst expectations. The stock reacted negatively, dropping 2.69% the following day.

Management Promises & Guidance

Focus on advancing clinical trials for its lead programs.
Commitment to enhancing its base editing technology.
Plans to provide more transparency on future revenue projections.

Expectations

Wall Street Expectations

Overall, expectations are mixed as Beam has shown volatility in its earnings history. Investors are keenly watching for any signs of progress in clinical trials.

Bull Case

If Beam demonstrates significant advancements in its clinical trials, it could lead to increased investor confidence and a potential stock price rally.

Bear Case

Conversely, if the company fails to provide clear progress or misses expectations again, it could lead to further declines in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What progress has been made in clinical trials for Beam's lead programs?

The success or failure of these trials can heavily influence investor sentiment and the stock's future performance.

Will management provide updated revenue projections for the upcoming quarters?

Clear guidance on revenue can help investors gauge the company's growth trajectory and financial health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Beam's potential for clinical trial success, given its innovative base editing technology, which could lead to breakthroughs in treating genetic diseases.

Supporting Evidence

Beam's recent advancements in technology may not be fully reflected in current market expectations.

The options market is pricing in a larger move than historical averages suggest, indicating potential for a surprise.

Past performance shows that the company has a 50% beat rate, suggesting that positive surprises are possible.

Key Risk

If clinical trial results exceed expectations, it could significantly shift market sentiment in Beam's favor.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Beam's ability to translate its innovative technology into tangible financial results.

Bull Confirmed If

Demonstrating a clear path to commercialization for its lead programs would support a bullish outlook.

Bear Confirmed If

Failure to provide any positive updates on clinical trials or revenue guidance would confirm a bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±10.21%

Historical Avg

±6.2%

Pricing rich

The options market is pricing in a significant move, suggesting that traders anticipate volatility around the earnings report.

Options are pricing ±10.2% while BEAM has averaged ±6.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

74.1%

Calls (99K)P/C Ratio: 0.03Puts (3K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Beam beats expectations and raises guidance, history suggests a potential stock increase of around 2.09%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may react neutrally, reflecting the uncertainty.

Miss

A miss could lead to a decline of about 7.50%, indicating continued investor skepticism about the company's growth prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for lead programs.
2Any changes to revenue projections or guidance.
3Management's commentary on competitive positioning in the biotechnology space.
4Insights into partnerships or collaborations that could enhance growth.
5Future plans for product development and commercialization timelines.